You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

newly diagnosed carcinoma of unknown primary

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer of Unknown Primary Site, Unknown Primary Cancer, Unknown Primary, Squamous Cell Carcinoma Trial in Copenhagen, Århus

Recruiting
  • Cancer of Unknown Primary Site
  • +2 more
  • Transoral Ultrasound
  • Copenhagen, Denmark
  • +1 more
May 2, 2023

Non-hodgkin Lymphoma Trial (Methotrexate, Rituximab (where available), Ibrutinib)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • (no location specified)
Aug 11, 2023

ITP - Immune Thrombocytopenia Trial (hetrombopag 5mg po qd, High-dose Dexamethasone)

Not yet recruiting
  • ITP - Immune Thrombocytopenia
  • hetrombopag 5mg po qd
  • High-dose Dexamethasone
  • (no location specified)
Jul 5, 2023

PCNSL Trial in Shanghai (Zanubrutinib, Rituximab, Methotrexate)

Not yet recruiting
  • PCNSL
  • Shanghai, Shanghai, China
    Ruijin Hospital
Jun 8, 2023

Newly-diagnosed PCNSL Treated WithMethotrexate and

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Oct 30, 2023

Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 3, 2022

Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)

Completed
  • Primary Central Nervous System Lymphoma
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 18, 2022

Compensation to Maintain Cognitive Function in Adults Newly

Completed
  • Primary Brain Tumor
  • Brain Metastases, Adult
  • Neuropsychological Testing
  • Durham, North Carolina
    Duke University Medical Center
Jan 19, 2023

Carcinoma of Unknown Primary: A Comparison Across Tissue and

Recruiting
  • Cancer of Unknown Primary Site
    • Bath, United Kingdom
    • +6 more
    Oct 18, 2022

    Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Orelabrutinib,Rituximab and Methotrexate
    • Beijing, Beijing, China
      Hospital 307
    Sep 19, 2022

    Carcinoma of Unknown Primary Trial in Calgary, Edmonton, Ottawa (Pembrolizumab Injection)

    Recruiting
    • Carcinoma of Unknown Primary
    • Pembrolizumab Injection
    • Calgary, Alberta, Canada
    • +2 more
    Feb 18, 2022

    Hepatocellular Carcinoma Trial in Tampa (Selinexor Pill, Bevacizumab, Atezolizumab)

    Recruiting
    • Hepatocellular Carcinoma
    • Selinexor Pill
    • +2 more
    • Tampa, Florida
      Moffitt Cancer Center
    Aug 16, 2022

    Breast Carcinoma, Metastatic Breast Cancer, Invasive Breast Cancer Trial in Obninsk (Device: Radiation: Diffusing Alpha

    Recruiting
    • Breast Carcinoma
    • +3 more
    • Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
    • Obninsk, Kaluga Region, Russian Federation
      A. Tsyb Medical Radiological Research Center
    Feb 16, 2022

    Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Methotrexate (MTX))

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Shanghai, Shanghai, China
      Department of Hematology, Huashan Hospital, Fudan University
    Jul 26, 2022

    Ovarian Cancer Trial in Birmingham (Carboplatin, olaparibp, embro)

    Not yet recruiting
    • Ovarian Cancer
    • Birmingham, Alabama
      O'Neal Comprehensive Cancer Center at UAB
    Jul 18, 2023

    Ovarian Cancer Trial (Gleolan)

    Not yet recruiting
    • Ovarian Cancer
    • (no location specified)
    Mar 27, 2023

    Extensive Small Cell Lung Cancer Trial in Jinan (Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy)

    Recruiting
    • Extensive Small Cell Lung Cancer
    • Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy
    • Jinan, Shan Dong, China
      The First Affiliated Hospital of Shandong First Medical Universi
    Nov 6, 2023

    Head Neck Cancer, Unknown Primary Cancer, Head and Neck Squamous Cell Carcinoma Trial in Dallas (Pegsitacianine)

    Not yet recruiting
    • Head and Neck Cancer
    • +2 more
    • Dallas, Texas
      University of Texas Southwestern Medical Center
    Jan 18, 2023

    Metastatic Colorectal Carcinoma, Neuropathy Trial (BXQ-350, Placebo)

    Recruiting
    • Metastatic Colorectal Carcinoma
    • Neuropathy
    • Edgewood, Kentucky
    • +5 more
    Jan 18, 2023

    Atypical Choroid Plexus Papilloma, Choroid Plexus Carcinoma Trial in New York (Melphalan, Carboplatin, Topotecan)

    Recruiting
    • Atypical Choroid Plexus Papilloma
    • Choroid Plexus Carcinoma
    • New York, New York
      Weill Cornell Medicine
    Aug 16, 2022

    China With Non-Small-Cell Lung Cancer That is Unable to be

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
      • (no location specified)
      May 16, 2023

      Nasopharyngeal Carcinoma Trial in Guangzhou (drug, radiation, procedure)

      Recruiting
      • Nasopharyngeal Carcinoma
      • Guangzhou, Guangdong, China
      • +1 more
      Jun 28, 2022

      Oropharyngeal Squamous Cell Carcinoma (SCC) Trial run by the National Cancer Institute (NCI) (PRGN-2009, Pembrolizumab)

      Not yet recruiting
      • Oropharyngeal Squamous Cell Carcinoma (SCC)
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Aug 22, 2023

      Nasopharyngeal Carcinoma Trial in Guangzhou (Immunotherapy+induction chemo+radiotherapy)

      Not yet recruiting
      • Nasopharyngeal Carcinoma
      • Immunotherapy+induction chemotherapy+radiotherapy
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Jun 9, 2022

      Circulating Biomarkers in Oropharyngeal Cancers

      Active, not recruiting
      • Oropharynx Squamous Cell Carcinoma
      • +3 more
        • Orebro, Sweden
          Anna Oldaeus Almerén
        Jun 13, 2023